BMP9 inhibits proliferation and metastasis of HER2-positive SK-BR-3 breast cancer cells through ERK1/2 and PI3K/AKT pathways

PLoS ONE

Volumn 9, Issue 5, 2014, Pages

  Ren, Wei ^a   Liu, Yuehong ^a   Wan, Shaoheng ^a   Fei, Chang ^a   Wang, Wei ^a   Chen, Yingying ^a   Zhang, Zhihui ^a   Wang, Ting ^a   Wang, Jinshu ^a   Zhou, Lan ^a   Weng, Yaguang ^a   He, Tongchuan ^b   Zhang, Yan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

^b UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 9; MITOGEN ACTIVATED PROTEIN KINASE 1; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GDF2 PROTEIN, HUMAN; GROWTH DIFFERENTIATION FACTOR; MESSENGER RNA; ONCOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; CANCER GROWTH; CARCINOGENESIS; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INACTIVATION; FEMALE; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; METASTASIS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; APOPTOSIS; BIOSYNTHESIS; BREAST NEOPLASMS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; PATHOLOGY;

APOPTOSIS; BREAST NEOPLASMS; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GROWTH DIFFERENTIATION FACTORS; HUMANS; MAP KINASE SIGNALING SYSTEM; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; ONCOGENE PROTEIN V-AKT; PHOSPHATIDYLINOSITOL 3-KINASES; RECEPTOR, ERBB-2; RNA, MESSENGER;

EID: 84900523990     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0096816     Document Type: Article

References (35)

1. Zhang YJ (2012) The molecular subtype of breast cancer. Prac J Can 27: 98-100.
2. Sehdev V, Lai JC, Bhushan A (2009) Biochanin A Modulates Cell Viability, Invasion, and Growth Promoting Signaling Pathways in HER-2-Positive Breast Cancer Cells. J Oncol 2009: 121458.
3. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, et al. (2009) The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist 14: 320-368.
4. Lai HW, Chien SY, Kuo SJ, Tseng LM, Lin HY, et al. (2012) The Potential Utility of Curcumin in the Treatment of HER-2-Overexpressed Breast Cancer: An In Vitro and In Vivo Comparison Study with Herceptin. Evid Based Complement Alternat Med 2012: 486568.
5. Merkhofer EC, Cogswell P, Baldwin AS (2010) Her2 activates NF-kappaB and induces invasion through the canonical pathway involving IKKalpha. Oncogene 29: 1238-1248.
6. Fan P, McDaniel RE, Kim HR, Clagett D, Haddad B, et al. (2012) Modulating therapeutic effects of the c-Src inhibitor via oestrogen receptor and human epidermal growth factor receptor 2 in breast cancer cell lines. Eur J Cancer 48: 3488-3498.
7. Ghosh R, Narasanna A, Wang SE, Liu S, Chakrabarty A, et al. (2011) Trastuzumab has preferential activity against breast cancers driven by HER2 homodimers. Cancer Res 71: 1871-1882.
8. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-792. (Pubitemid 32222155)
9. Piccart-Gebhart MJ, Procter M, Leyland-Jones B, Goldhirsch A, Untch M, et al. (2005) Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 353: 1659-1672. (Pubitemid 41464705)
10. Romond EH, Perez EA, Bryant J, Suman VJ, Geyer CE Jr, et al. (2005) Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 353: 1673-1684. (Pubitemid 41464706)
11. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, et al. (1998) Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 16: 2659-2671. (Pubitemid 28363029)
12. Cobleigh MA, Vogel CL, Tripathy D, Robert NJ, Scholl S, et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639-2648. (Pubitemid 29415219)
13. Wang K, Feng H, Ren W, Sun X, Luo J, et al. (2011) BMP9 inhibits the proliferation and invasiveness of breast cancer cells MDA-MB-231. J Cancer Res Clin Oncol 137: 1687-1696.
14. Ye L, Bokobza SM, Jiang WG (2009) Bone morphogenetic proteins in development and progression of breast cancer and therapeutic potential (review). Int J Mol Med 24: 591-597.
15. Li B, Yang Y, Jiang S, Ni B, Chen K, et al. (2012) Adenovirus-mediated overexpression of BMP-9 inhibits human osteosarcoma cell growth and migration through downregulation of the PI3K/AKT pathway. Int J Oncol 41: 1809-1819.
16. Reddi AH, Reddi A (2009) Bone morphogenetic proteins (BMPs): from morphogens to metabologens. Cytokine Growth Factor Rev 20: 341-342.
17. Wagner DO, Sieber C, Bhushan R, Borgermann JH, Graf D, et al. (2010) BMPs: from bone to body morphogenetic proteins. Sci Signal 3: mr1.
18. Moasser MM (2007) The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis. Oncogene 26: 6469-6487.
19. Ross JS, Fletcher JA, Linette GP, Stec J, Clark E, et al. (2003) The Her-2/neu gene and protein in breast cancer 2003: biomarker and target of therapy. Oncologist 8: 307-325. (Pubitemid 36929717)
20. Kang MH, Oh SC, Lee HJ, Kang HN, Kim JL, et al. (2011) Metastatic function of BMP-2 in gastric cancer cells: the role of PI3K/AKT, MAPK, the NF-kappaB pathway, and MMP-9 expression. Exp Cell Res 317: 1746-1762.
21. Adeyinka A, Nui Y, Cherlet T, Snell L, Watson PH, et al. (2002) Activated mitogen-activated protein kinase expression during human breast tumorigenesis and breast cancer progression. Clin Cancer Res 8: 1747-1753. (Pubitemid 34633730)
22. Meng Q, Xia C, Fang J, Rojanasakul Y, Jiang BH (2006) Role of PI3K and AKT specific isoforms in ovarian cancer cell migration, invasion and proliferation through the p70S6K1 pathway. Cell Signal 18: 2262-2271. (Pubitemid 44636166)
23. Chao X, Zao J, Xiao-Yi G, Li-Jun M, Tao S (2010) Blocking of PI3K/AKT induces apoptosis by its effect on NF-kappaB activity in gastric carcinoma cell line SGC7901. Biomed Pharmacother 64: 600-604.
24. Osaki M, Oshimura M, Ito H (2004) PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9: 667-676. (Pubitemid 40941196)
25. Seshadri R, Firgaira FA, Horsfall DJ, McCaul K, Setlur V, et al. (1993) Clinical significance of HER-2/neu oncogene amplification in primary breast cancer. The South Australian Breast Cancer Study Group. J Clin Oncol 11: 1936-1942. (Pubitemid 23304619)
26. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, et al. (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235: 177-182. (Pubitemid 17231334)
27. Ye L, Kynaston H, Jiang WG (2008) Bone morphogenetic protein-9 induces apoptosis in prostate cancer cells, the role of prostate apoptosis response-4. Mol Cancer Res 6: 1594-1606.
28. Li Q, Gu X, Weng H, Ghafoory S, Liu Y, et al. (2013) Bone morphogenetic protein-9 induces epithelial to mesenchymal transition in hepatocellular carcinoma cells. Cancer Sci 104: 398-408.
29. Imai K, Takaoka A (2006) Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6: 714-727. (Pubitemid 44286003)
30. Kuo HP, Hsu SC, Ou CC, Li JW, Tseng HH, et al. (2013) Ganoderma tsugae Extract Inhibits Growth of HER2-Overexpressing Cancer Cells via Modulation of HER2/PI3K/Akt Signaling Pathway. Evid Based Complement Alternat Med 2013: 219472.
31. Baselga J, Swain SM (2009) Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 9: 463-475.
32. Yang HL, Lin KY, Juan YC, Kumar KJ, Way TD, et al. (2013) The anti-cancer activity of Antrodia camphorata against human ovarian carcinoma (SKOV-3) cells via modulation of HER-2/neu signaling pathway. J Ethnopharmacol 148: 254-265.
33. Zhou NN, Tang J, Chen WD, Feng GK, Xie BF, et al. (2012) Houttuyninum, an active constituent of Chinese herbal medicine, inhibits phosphorylation of HER2/neu receptor tyrosine kinase and the tumor growth of HER2/neu- overexpressing cancer cells. Life Sci 90: 770-775.
34. Meng X, Cai C, Wu J, Cai S, Ye C, et al. (2013) TRPM7 mediates breast cancer cell migration and invasion through the MAPK pathway. Cancer Lett 333: 96-102.
35. Lin Y, Cui H, Xu H, Yue L, Xu H, et al. (2012) Jolkinolide B induces apoptosis in MDA-MB-231 cells through inhibition of the PI3K/Akt signaling pathway. Oncol Rep 27: 1976-1980.